Earnings ·
Sera Prognostics reports Q3 revenue of $42,000 as test volume rises 54% sequentially
SERASera Prognostics, Inc.
Sera Prognostics reported fiscal third-quarter results ending September 30, 2026, with total PreTRM test revenue reaching $42,000, a 163% increase year-over-year. Test volumes grew 54% from the prior quarter and approximately five-fold from the first quarter of 2026. The company secured Medicaid coverage for its test in Florida, adding approximately 90,000 annual births to its covered population alongside existing Illinois coverage. Operating expenses declined 11% sequentially due to cost reductions implemented in June 2026, partially offset by increased commercial spending and $0.4 million in severance expenses. The company ended the quarter with $72.8 million in cash, equivalents, and marketable securities, reporting a net loss of $8.1 million and a cash burn from operations of $7.3 million. Sera Prognostics is a health diagnostics company focused on precision pregnancy care and early prediction of preterm birth risk.